Condition
Myeloid Malignancies clinical trials and research
As of November 12, 2026, Find a Trial lists 4 Myeloid Malignancies clinical trials that are recruiting, at sites in 2 countries (most in United States (3), China (1)). By phase: Phase 1/2 (2), Phase 2 (1), Phase 3 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 2Countries
Newest Myeloid Malignancies clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Adding venetoclax to fludarabine–melphalan conditioning for people over 50 with AML or MDS getting a donor stem cell transplant | Phase 3 | Fuzhou, Fujian and 17 other locations | Recruiting | Feb 9, 2026 |
| CAR.70 and IL-15 modified cord blood NK cell therapy with TGFBR2 knockout plus chemotherapy for relapsed or refractory myeloid cancers | Phase 1/2 | Houston, Texas | Recruiting | Apr 16, 2025 |
| Using olutasidenib as maintenance therapy after stem cell transplant for patients with IDH1-mutated myeloid malignancies | Phase 2 | Houston, Texas | Recruiting | Oct 31, 2024 |
| Engineered NK cells targeting PRAME for treating myeloid malignancies | Phase 1/2 | Houston, Texas | Recruiting | Apr 25, 2024 |
All recruiting trials (4)
-
Adding venetoclax to fludarabine–melphalan conditioning for people over 50 with AML or MDS getting a donor stem cell transplant
This tests whether adding venetoclax to standard fludarabine–melphalan conditioning helps people over 50 with AML or MDS who are having an allogeneic stem cell transplant.
-
CAR.70 and IL-15 modified cord blood NK cell therapy with TGFBR2 knockout plus chemotherapy for relapsed or refractory myeloid cancers
This will test a one-time infusion of genetically modified cord blood NK cells given after lymphodepleting chemotherapy to see if it helps adults with relapsed or refractory AML, MDS, or CMML.
-
Using olutasidenib as maintenance therapy after stem cell transplant for patients with IDH1-mutated myeloid malignancies
This study is testing if olutasidenib can help prevent relapse in patients with IDH1-mutated myeloid cancers after they have had a stem cell transplant.
-
Engineered NK cells targeting PRAME for treating myeloid malignancies
This study is testing a new type of immune cell treatment for people with tough-to-treat blood cancers like acute myeloid leukemia and myelodysplastic syndromes to see how well it works and how safe it is.
Related topics
Quick answers
How many Myeloid Malignancies clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in United States (3 trials), China (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1/2: 2, Phase 2: 1, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.